Cantor Fitzgerald lowers Regeneron stock price target on Eylea concerns

Cantor Fitzgerald lowered its Regeneron (REGN) price target to $750 from $785 (maintaining Overweight), while noting negative optics risks from potential Eylea HD/SD and Dupixent misses vs consensus and unclear Eylea HD PFS messaging. The stock is ~$654, trading below the new target, and the firm points to upside from Sanofi collaboration revenue/EPS and valuation support. Near-term catalysts include focus on gMG launch framing and upcoming GA readout, alongside additional biotech updates (EMA accepted Otarmeni gene therapy for Accelerated Assessment).

Analysis

The market is treating this as a credibility problem more than a balance-sheet problem. For REGN, the immediate risk is not liquidation-style downside; it is multiple compression if investors conclude the core franchise is losing pricing power and management visibility is deteriorating. That said, the stock’s cash-rich profile and collaboration income make it harder to build a deep bear case without a clear inflection in operating metrics, so the cleaner expression is relative underperformance versus higher-beta biotech rather than an outright collapse.

Second-order, the pressure spills into adjacencies: SNY shares the economic engine on Dupixent, so any real demand deceleration would hit both sides, but REGN likely absorbs the larger valuation hit because it carries the broader pipeline disappointment discount. CTMX is a small but real beneficiary of the collaboration expansion, though the stock likely trades more on financing and execution than on the headline payment; useful as a sentiment read-through, not a standalone catalyst. The key time horizons are days for the sell-side narrative, 1-3 months for earnings/guidance and upcoming data presentations, and 6-18 months for whether new assets can re-anchor growth after Eylea maturation.

Contrarian view: consensus may be underestimating how much optionality is already embedded in REGN’s valuation. If management can show cleaner launch execution and one credible late-stage win, the stock can re-rate quickly because it is not priced like a zero-growth story. The thesis breaks if the next print shows stable Dupixent growth, clearer Eylea HD conversion, and pipeline updates that reduce the market’s reliance on a single franchise to justify the multiple.

Key Decisions for Investors

• Sell REGN strength into any post-note bounce; use a 1-3 month horizon and target a relative short versus IBB/XBI rather than an outright short, since balance-sheet support limits downside asymmetry.
• If entering a bearish options expression, prefer REGN 1-2 month put spreads over naked puts; the expected move looks more like multiple compression than a fundamental air pocket, so defined risk is better.
• Watch for a reversal signal at the next earnings/guidance event: if REGN re-accelerates core franchise growth or clears up launch messaging, cover shorts on a close above the prior post-warning high and reassess.
• Tactical long CTMX only as a catalyst-driven trade on collaboration validation; size small and treat it as a financing-sensitive name with higher execution risk than fundamental upside.
• No clear standalone trade in SNY yet; only consider a REGN/SNY relative-value pair if there is evidence the Dupixent issue is demand-related rather than optics-related.